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Abstract 16 
Importance: The likelihood of achieving a live-birth with repeat in-vitro fertilisation (IVF) is 17 
unclear, yet the number of treatment is commonly limited to three or four embryo transfers. 18 
Objective: To determine the live-birth rate per initiated IVF cycle and with repeated cycles. 19 
Design: Prospective study of 156,947 UK women who received 257,398 IVF treatment 20 
cycles between 2003 and 2010 and were followed until June 2012. 21 
Main exposure: IVF, with a cycle defined as an episode of ovarian stimulation and all 22 
subsequent separate fresh and frozen embryo transfers. 23 
Main Outcome(s): Live-birth rate per IVF cycle and the cumulative live-birth rate across all 24 
cycles in all women and by age and treatment type.  25 
Results: In all women the live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 29.7). 26 
This remained above 20% up to and including the fourth cycle. The cumulative live-birth rate 27 
across all cycles continued to increase up to the ninth, with 78.0% (77.3, 78.8) of women 28 
achieving a live-birth by the sixth cycle. In women younger than 40 using their own oocytes, 29 
the live-birth rate for the first cycle was 32.3% (32.0, 32.5), and remained above 20% up to 30 
and including the fourth cycle. Six cycles achieved a cumulative live-birth rate of 80.3% 31 
(79.5, 81.0). For women aged 40-42, the live-birth rate for the first cycle was 12.3% (95%CI: 32 
11.8, 12.8), with six cycles achieving a cumulative live-birth rate of 41.5% (38.0, 44.9). For 33 
women older than 42 years all rates within each cycle were less than 4%. Use of donor 34 
oocytes removed the age differential. Rates were lower in those with untreated male factor 35 
infertility compared to those with any other cause, but treatment with either intra-cytoplasmic 36 
sperm injection or sperm donation removed this difference. 37 
Conclusions and relevance: Among women in the UK undergoing IVF, the cumulative live-38 
birth rate after six cycles was 78.0%, with variations by age and treatment type. These 39 
findings support the efficacy of extending the number of IVF cycles beyond three or four.  40 
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Introduction 41 
In-vitro fertilization (IVF) is commonly stopped after three or four unsuccessful embryo 42 
transfers,1,2 with three unsuccessful transfers labelled ‘repeat implantation failure’.3 This 43 
practice has been influenced by a study of 1,328 embryo transfers undertaken twenty-years 44 
ago, without use of intra-cytoplasmic sperm injection (ICSI), which reported a decline in 45 
live-birth rates after the fourth cycle.4 With one exception,5 previous studies of cumulative 46 
pregnancy or live-birth rates have been relatively small, with limited ability to precisely 47 
estimate cumulative success beyond four transfers.4,6-9  Previous studies have defined a cycle 48 
of IVF as an embryo transfer.5-9 Thus, each initiation of IVF treatment has been treated as 49 
several separate cycles whenever there has been a series of repeated embryo transfers. Given 50 
the promotion of single embryo transfer and the effective freezing of embryos have increased 51 
markedly over the last 10-15 years,10-15 it has been suggested that IVF success should be 52 
calculated as the live-birth rate per initiated ovarian stimulation treatment, including all 53 
subsequent separate fresh and frozen embryo transfers.5,10-13  54 
 55 
The aim of this study was to determine the extent to which repeat IVF cycles continue to 56 
increase the likelihood of a live-birth, defining an IVF cycle as the initiation of treatment with 57 
ovarian stimulation and all resulting separate fresh or frozen embryo transfers; hereafter we 58 
use the term “cycle” for this. Specific objectives were to determine: (i) the live-birth rate 59 
within each cycle, and the cumulative rate across all cycles; (ii) how these varied by age and 60 
treatment types (use of donor oocyte, ICSI or sperm donation); (iii) the association between 61 
oocyte yield in one cycle and live-birth rate in subsequent cycles; and (iv) to compare 62 
cumulative live-birth rates with IVF to published rates in women conceiving naturally.  63 
 64 
Methods 65 
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Ethical approval for this study was provided by the UK Human Fertilisation and Embryology 66 
Authority (HFEA) who have statutory obligations to prospectively collect information on all 67 
assisted reproductive treatment (ART) in the UK. Women provided written consent for this 68 
information to be used in analyses, audit and publications. The HFEA provided us with data 69 
on all ART events occurring in the UK between 1st January 2003 and 30th June 2012, with 70 
linkage of cycles to individual women and data on birth outcomes. Because all UK clinics, 71 
whether private or public, must provide information on any patients treated with ART, 72 
together with the outcomes of that treatment, to the HFEA, they are able to link cycles to 73 
individual women for all UK ART. We chose the 2003 start date in order to obtain a large 74 
cohort representative of contemporary treatment, and June 2012 was the latest date for which 75 
the HFEA could provide validated data. Because the live-birth outcome data were incomplete 76 
for cycles commencing between January 2011 and June 2012 (as many of these cycles were 77 
still continuing and births from them could occur after June 2012) we limited our potentially 78 
eligible cohort to treatment initiated between 1st January 2003 and 31st December 2010, with 79 
live-birth outcome data collected up to June 2012.  80 
 81 
We excluded ART that was not IVF or was undertaken for the purpose of storage, donation 82 
or surrogacy. We excluded women who had started treatment before 2003. As in other 83 
studies,5-9 once a live-birth occurred women were censored from further analysis. To reflect 84 
clinical practice and allow comparisons with other studies,4,5,7,9 we included all embryo 85 
transfers, whether the individual transfer was of one or more embryos. 86 
 87 
Live-birth was defined as a baby born alive after 24 weeks gestation surviving more than one 88 
month. The World Health Organisation (WHO) define live-birth as a birth showing any sign 89 
of life irrespective of gestational age. As in other studies,5, 15,16 we modified this to capture 90 
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births that were likely to be viable. We defined an IVF cycle as the initiation of treatment 91 
with ovarian stimulation and all resulting separate fresh or frozen embryo transfers. The live-92 
birth rate within a cycle was defined as the probability of a live-birth from an ovarian 93 
stimulation encompassing all subsequent fresh and frozen embryo transfers from that 94 
stimulation. Thus, for those embarking on treatment the live-birth rate within one cycle 95 
answers the question ‘What is my chance of a live-birth with one stimulation and retrieval of 96 
oocytes followed by as many subsequent separate embryo transfers as possible from that 97 
retrieval?’ The cumulative live-birth rate at a given cycle was defined as the probability of a 98 
live-birth from all cycles up to and including that cycle. This answers the question ‘What is 99 
my total chance of a live-birth with repeat ovarian stimulation and oocyte retrievals, together 100 
with the subsequent embryo transfers from each cycle, up to a given cycle number?’.  101 
 102 
Information on age, types of treatment (oocyte donation, sperm donation and ICSI), oocyte 103 
yield and other couple characteristics were obtained from the HFEA dataset. 104 
 105 
Statistical methods 106 
We calculated the live-birth rates within the first and subsequent cycles up to the ninth, as the 107 
proportion of cycles resulting in a live-birth, using a normal approximation to construct 108 
confidence intervals. We calculated the cumulative live-birth rate, up to the ninth cycle, using 109 
the Kaplan-Meier method with Greenwood’s approximation to calculate confidence intervals 110 
(see online supplementary material for full details).17,18 We compared the live-birth rate 111 
within each cycle and cumulatively across all cycles between age and treatment type 112 
categories using a log-rank test.19 We assessed the relationship of oocyte yield in one cycle to 113 
live-birth rates in subsequent cycles in women younger than 40 years using their own 114 
oocytes, by calculating the within live-birth rate in the first, second, and third cycles by 115 
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oocytes retrieved in the first cycle, and also calculating the within live-birth rate up to the 116 
fifth cycle by oocytes retrieved in the immediately preceding cycle. 117 
 118 
Dealing with discontinuation of IVF 119 
We calculated ‘optimal’, ‘conservative’ and ‘prognostic-adjusted’ estimates of the cumulative 120 
live-birth rate. The optimal estimate assumes the cumulative live-birth rate in women who 121 
discontinue treatment without a live-birth is equal to the rate in those who continue to have 122 
further cycles.5 The conservative estimate assumes those who discontinue treatment have a 123 
subsequent live-birth rate of zero.5 The true rate is thought to lie between these two 124 
extremes.7 The prognostic-adjusted estimate aims to obtain this more realistic value. It 125 
assumes a fixed proportion of those who discontinue treatment do so because of poor 126 
prognosis and that the live-birth rate in that proportion will be zero, whereas for those who 127 
discontinue for other reasons, such as inability to pay, emotional distress or (in our dataset) 128 
emigration from the UK, the live-birth rate will be similar to those who continue with 129 
treatment.  130 
 131 
We considered the woman’s age at her first cycle and oocyte yield in the previous cycle to be 132 
the strongest prognostic factors, because these have been shown to be strongly related to live-133 
birth success.5,7,9,20,21 We checked that these were indicators of live-birth and of 134 
discontinuation of treatment in our own data, as well as comparing other available 135 
characteristics between those who discontinued and continued treatment after one 136 
unsuccessful cycle. To adjust for age and oocyte yield in the previous cycle we calculated 137 
results within categories and then obtained an average, weighted by the numbers within each 138 
category in the first cycle.  139 
 140 
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We used the adjusted live-birth rate to estimate the proportion of those who discontinued 141 
treatment because of poor prognosis. This provided an estimate of the proportion who 142 
discontinued because of poor prognosis of 3%. However, to calculate a prognostic-adjusted 143 
cumulative live-birth rate we assumed 30% of those who discontinued treatment did so 144 
because of poor prognosis. We chose a value of ten-times that suggested by our data to obtain 145 
a reasonably conservative prognostic-adjusted estimate. Full details of how all of the 146 
estimates were calculated are provided in online supplementary material. 147 
 148 
As the average population live-birth success rate for a single embryo transfer is between 20-149 
30% in high income countries,10-13 we considered 20% to be a benchmark for a good live-150 
birth rate within a cycle. All analyses were undertaken in Stata version 13 MP2. Two-sided p-151 
values < 0.05 were considered to provide evidence against the null hypothesis. 152 
 153 
Comparison with live-birth rates in those not receiving ART 154 
We used data from published literature to estimate live-birth rates in women who conceive 155 
naturally.22-24 Full details of how we calculated these estimates are provided in online 156 
supplementary material.  157 
 158 
Results 159 
Following planned exclusions the eligible cohort included 257,665 cycles in 157,475 women. 160 
For all analyses we excluded women with missing linkage information or implausible linkage 161 
(i.e. first IVF transfer being a frozen embryo transfer without preceding ovarian stimulation). 162 
This resulted in an analysis cohort of 257,398 cycles by 156,947 women (more than 99% of 163 
the eligible cohort; Figure 1). Table 1 shows the characteristics of the cohort at the first 164 
cycle and also for all cycles. eTable 1 shows characteristics by year of treatment. Because of 165 
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the large sample size there was statistical evidence of differences in all characteristics, but for 166 
most these were small and unlikely to be clinically important. For example, median age of the 167 
women differed by one-year and median oocyte retrieval differed by one across the whole 168 
study period between 2003 and 2010. Use of ICSI increased by 11%, and transfer of single 169 
embryos by 17%, though the live-birth rate increased by just two-percent across the study 170 
period.  171 
 172 
Table 2 shows the live-birth rate within each cycle and cumulatively across all cycles for the 173 
whole cohort. In all women the live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 174 
29.7). The live-birth rate within cycles remained above 20% for each cycle up to and 175 
including the fourth. After their first cycle there were 110,614 women (70.5% of the analysis 176 
cohort) who did not have a live-birth. Of these, 37,704 (34.1%) discontinued treatment and 177 
72,910 (65.9%) had at least one more cycle. eTable 2 compares characteristics between these 178 
two groups. Although there was statistical evidence of differences for all characteristics the 179 
actual differences were small; e.g. women who discontinued treatment were one-year older 180 
and had median of one fewer oocytes retrieved per cycle. The proportion who used donor 181 
oocytes was higher in those who discontinued treatment (3.7% vs 1.3%). The age-adjusted 182 
and optimal cumulative live-birth rate estimates were similar (Table 2 and eFigure 1). 183 
eFigure 2 shows the cumulative live-birth rates assuming 0% (equivalent to the optimal), 3% 184 
(as suggested by our analyses), 30% (used for our prognostic-adjusted estimate) and 100% 185 
(equivalent to the conservative) of those who discontinue treatment do so for poor prognosis. 186 
Six cycles achieved cumulative live-birth rates of 78.0% (77.3, 78.8), 46.8% (46.5, 47.0) and 187 
65.3% (64.8, 65.8), by the optimal, conservative and prognostic-adjusted estimates, 188 
respectively (Table 2). 189 
 190 
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Results varied by age and oocyte source (Figure 2). In women who were younger than 40 191 
years and using their own oocytes (133,379 women, 85% of the cohort), the live-birth rate for 192 
the first cycle was 32.3% (32.0, 32.5). This remained above 20% up to and including the 193 
fourth cycle. The previous cycle oocyte-yield adjusted and optimal estimates were similar 194 
(Table 3). Six cycles achieved cumulative live-birth rates of 80.3% (79.5 to 81.0), 50.7% 195 
(50.5, 51.0) and 68.4%, (67.8, 68.9), by the optimal, conservative and prognostic-adjusted 196 
estimate, respectively (Table 3). For women aged 40-42, the live-birth rate for the first cycle 197 
was 12.3% (11.8, 12.8), with six cycles achieving a cumulative live-birth rates of 41.5% 198 
(38.0, 44.9), 19.2% (18.5, 19.8) and 31.5% (29.7, 33.3), for optimal, conservative and 199 
prognostic-adjusted estimates, respectively (eTable 3). For women older than 42 years all 200 
rates within each cycle were less than 4% or based on too few live-births to calculate 201 
confidence intervals (eTable 4). Use of donor oocytes removed the age differential (p = 0.34 202 
for difference between women in the youngest and middle age categories using donor oocytes 203 
and p = 0.89 for difference between women in the middle and oldest categories). Irrespective 204 
of age, women using donor oocytes achieved live-birth rates within each cycle of  29.6% or 205 
greater for all cycles up to and including the ninth and a cumulative live-birth rate after six 206 
cycles of 91.7% (90.3, 93.1), 75.5% (74.0, 77.1) and 86.7% (85.2, 88.3), for the optimal, 207 
conservative and prognostic-adjusted estimates, respectively (eTable5).  208 
 209 
Live-birth rates varied by male cause infertility and its treatment (Figure 3 and eTables 6 to 210 
9). Women whose infertility was due to a male related cause and who were not treated with 211 
either ICSI or donor sperm had lower live-birth rates than those with a non-male cause of 212 
infertility (eTable 6 p < 0.001 for log-rank test). Those with a male cause of infertility who 213 
were treated with ICSI had cumulative live-birth rates, after six cycles, of 82.2% (81.1, 83.4),  214 
54.7% (54.3, 55.2) and 71.3% (70.5, 72.1), using the optimal, conservative, and conservative 215 
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prognostic-adjusted estimates, respectively (eTable 7). Equivalent results for those with male 216 
infertility treated with donor sperm were 90.2% (87.2, 93.1), 65.9% (63.9, 67.9) and 81.2% 217 
(78.6, 83.9), respectively (eTable 8). Live-birth rates in both of these groups were greater 218 
than in those with a non-male cause of infertility (eTable 9, p < 0.001 for both log-rank 219 
tests).  220 
 221 
Figure 4 shows the live-birth rate within the first, second and third cycles plotted against the 222 
number of oocytes retrieved in the first cycle in women under 40 years of age using their own 223 
oocytes. For those in whom no oocytes were retrieved in the first cycle the live-birth rates in 224 
the second and third cycles were greater than 20%. The live-birth rates in the first, second and 225 
third cycles continued to increase with increasing oocytes retrieved in the first cycle up to 226 
around 15 oocytes; thereafter the curves flatten. Plotting the live-birth rate within any cycle 227 
against the number of oocytes retrieved in the immediately previous cycle gave a similar 228 
pattern (eFigure 3). 229 
 230 
Using published data22-24 we estimated that the live-birth rate for women conceiving 231 
naturally, and who had been trying for 12 menstrual cycles, varied between 58% and 74% 232 
depending on the woman’s age and frequency of intercourse (eTable 10). These estimates are 233 
based on studies that only included women younger than 40 years. Similar cumulative live-234 
birth rates were achieved by the fourth or fifth cycle of IVF treatment in women of this age 235 
(Table 3), though, in these women, five cycles took a median of 2 years (1st, 3rd quartile: 2, 236 
3). 237 
 238 
Discussion 239 
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To our knowledge this is the first study to have linked fresh and frozen embryo transfers to 240 
obtain estimates of live-birth rate within each IVF ovarian stimulation cycle and cumulative 241 
live-birth rates across repeated stimulation cycles. Despite a decline in the success rate within 242 
each cycle as the number of these increased, the cumulative rate across cycles increased up to 243 
the ninth in the whole cohort, those younger than 40 years (using their own oocytes) and 244 
those using donor oocytes (irrespective of age). They also increased up to the eighth or ninth 245 
in women aged 40-42, though for women older than 42 (using their own oocytes) the 246 
likelihood of success was low and the cumulative live-birth rate did not appear to clearly 247 
increase beyond the fourth or fifth cycle. For those women prepared, and able, to use donor 248 
oocytes, age was unrelated to success. Similarly, in those for whom the cause of infertility 249 
was related to a male partner problem, treatment with ICSI or donor sperm made a marked 250 
difference in the likelihood of success, with cumulative rates increasing up to the eighth or 251 
ninth cycle, whereas without treatment rates were lower than in those with other causes of 252 
infertility. In women under 40 years with a low oocyte yield in a previous cycle there was 253 
benefit in continuing with further cycles. We also found women under 40 years could achieve 254 
cumulative live-birth rates after four or five cycles that were similar to published live-birth 255 
rates achieved naturally within 12 menstrual cycles.22-24 It should be noted, however, that, in 256 
these women, five cycles took a median of 2 years. 257 
     258 
Widespread adoption of single embryo transfer has reduced multiple pregnancies and adverse 259 
perinatal outcomes, but has meant that the chance of a live-birth from a single ovarian 260 
stimulation cycle is spread across multiple embryo transfers, which we have assessed here. 261 
Since this method of assessing IVF success combines all embryo transfer events following an 262 
ovulation stimulation into one analysis unit, we were unable to examine the effect of the 263 
number of embryos transferred per event. However, the method of assessing IVF success that 264 
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we have used is increasingly recommended,5,10-13 as it reflects the reality of contemporary 265 
IVF treatment. Our results show how success rates per embryo transfer event are 266 
misleadingly lower, compared with the rate within each ovarian stimulation cycle. 267 
Furthermore, we have previously shown, using unlinked data from the same population, that 268 
the number of embryos transferred in one event has a relatively modest effect on live-birth 269 
rate, with a difference of 9% in women younger than 40 years and 16% in those aged 40 270 
years or older, comparing double to single embryo transfer.15  271 
 272 
Despite the differences in the definition of cumulative success between our study and the 273 
previous largest study (from the US), in which cumulative live-birth rates were estimated on 274 
the basis of each embryo transfer,5 and differences in health systems between the US and UK, 275 
both studies found similar age differences in rates and that these were removed with the use 276 
of donor oocytes. In the US study, those with a male cause of infertility had one of the 277 
highest cumulative live-birth rates per embryo transfer event, but that study did not examine 278 
the effect of different treatments (ICSI or sperm donation) and it may be that all of those with 279 
male cause infertility in the US receive one of these treatments.  280 
 281 
The key limitation of all studies looking at cumulative outcomes with repeat IVF is how one 282 
treats those who discontinue treatment. We examined the likelihood that such discontinuation 283 
was due to poor prognosis based on age and previous cycle oocyte retrieval, both factors 284 
shown in previous studies to be important predictors of success, 5,7,9,20,21 and confirmed in our 285 
data to be related to live-births (Figures 2 and 4). These analyses suggested approximately 286 
3% of those who discontinued did so because of poor prognosis. This small proportion was 287 
because although these two were important predictors of live-birth, the poor prognosis levels 288 
of these exposures were uncommon.  Only 15% of women were 40-years or older and the 289 
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median oocyte retrieval was 9 per cycle. However, to account for other factors, for example 290 
pre-treatment reproductive hormone levels, smoking and body mass index (BMI), which have 291 
been linked to live-birth success, 7,21 but that were not available in this study, we assumed a 292 
30% discontinuation of treatment due to poor prognosis. Even assuming this much higher 293 
level of discontinuation, our results show high cumulative success rates, particularly in 294 
women under 40 years, with repeat ovarian stimulation up to the sixth such cycle. Because of 295 
the legal requirement for all UK clinicians to provide data on all ART patients, the HFEA 296 
were able to link cycles to individual women even if they move between clinics within the 297 
UK. However, treatment abroad would be absent from our data. A European study, 298 
conducted 6 years ago, found very few UK couples travelled for ART to 49 clinics in six 299 
(non-UK) European countries with high rates of cross-border patients.27 We were only able to 300 
assess live-birth as an outcome: future studies should also consider potential adverse effects 301 
of continued treatment, including ovarian hyper-stimulation syndrome and possible increased 302 
risk of preterm birth, low birth weight or congenital anomalies.16,25,26  303 
 304 
We acknowledge that for some couples the emotional stress of repeat treatments may be 305 
undesirable and the cost of a prolonged treatment course, with several repeat oocyte 306 
stimulation cycles, may be unsustainable for health services, insurers or couples. Though our 307 
results show that the median time to complete five ovarian stimulation treatments, with all 308 
subsequent embryo transfers is just 2-years. We feel the potential for success with further 309 
cycles should be discussed with couples. A cost-effectiveness analysis is beyond the scope of 310 
this paper, and the difficulties of undertaking such analyses for IVF treatment, in which 311 
decisions related to how one values a new life and whether ‘benefits’ and ‘costs’ for both 312 
parents and the child should be included, are well-documented.28 The costs of IVF treatment 313 
vary between countries, whether publicly or privately funded, and the treatment type used, 314 
but are in the range of $14,000 (£9,000, €12,000) to $17,000 (£11,000, €15,000) per 315 
14 
 
cycle.1,28,29 These costs exclude assessment prior to starting treatment and are based on 316 
transfer of one fresh embryo. Assuming each addition frozen embryo transfer costs $4000 to 317 
$5000,29 the cost per couple of continuing to six, rather than having just three cycles, could 318 
be as much as $132,000 compared to $66,000 (assuming one fresh and one frozen transfer 319 
per cycle). 320 
 321 
Conclusions 322 
Among women in the UK undergoing IVF, the cumulative live-birth rate continued to 323 
increase up to the ninth cycle for the whole cohort. The optimal, conservative and prognostic-324 
adjusted cumulative live-birth rates after six cycles were 78.0%, 46.8% and 65.3%, 325 
respectively. Results varied by age and treatment type, with women under 40 years using 326 
their own oocytes, those using donor oocytes (irrespective of age) and those treated with ICSI 327 
or sperm donation for a male cause of infertility, having broadly similar results to those for 328 
the whole cohort. These findings support the efficacy of extending the number of IVF cycles 329 
beyond three or four.  330 
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Figure descriptive titles and legends 427 
Figure 1: Definition of eligible and analysis cohort 428 
Figure 2: Cumulative live-birth rate across all initiated IVF cycles by age and oocyte 429 
source. 430 
The figure shows the optimal estimates of cumulative live-birth rates (i.e. the rate (shown on 431 
the y-axis) is the likelihood of a live-birth across all initiated cycles up to and including the 432 
numbers on the x-axis), with 95% confidence intervals. These are presented for women in 433 
two different age categories at the start of their first IVF treatment cycle (< 40 years and 40-434 
42 years; women in both of these categories used their own oocytes) and also in women who 435 
used donor oocytes (these women cover the full age range). Data for women aged over 42 at 436 
their first treatment cycle are not shown because rates were so low it would have been 437 
difficult to represent them on this same graph (full results for these women are shown in 438 
eTable 4). Analyses were completed in 156,947 women undergoing 257,398 cycles. 439 
Log-rank tests indicated a difference between the cumulative live-births rates for all groups 440 
(p < 0.001 for all comparisons). 441 
Figure 3: Cumulative live-birth rate across all initiated IVF cycles by ICSI and sperm 442 
donation. 443 
The figure shows the optimal estimates of cumulative live-birth rates (i.e. the rate (shown on 444 
the y-axis) is the likelihood of a live-birth across all initiated cycles up to and including the 445 
numbers on the x-axis), with 95% confidence intervals. These are shown for couples without 446 
a male cause of infertility, couples with a male cause who were not treated with ICSI or 447 
sperm donation, those with a male cause who were treated with ICSI and those with a male 448 
cause who used sperm donation. Analyses were completed in 156,947 women undergoing 449 
257,398 cycles. Log-rank tests indicated a difference between the cumulative live-births rates 450 
for all groups (p < 0.001 for all comparisons). 451 
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Figure 4: Live-birth rate within each single IVF treatment cycle by oocyte retrieval in 452 
first cycle. 453 
The figure shows the live-birth rate within each individual first, second and third treatment 454 
cycle (i.e. for each line the rate on the y-axis is the rate for just that one treatment cycle), 455 
against the number of oocytes retrieved in the first treatment cycle (shown on the x-axis). 456 
Analyses are in 134,903 women aged less than 40 years and using their own oocytes. Box 457 
and whiskers show the central 95% of the distribution of oocytes retrieved in the first cycle, 458 
as well as the median and lower and upper quartiles. 459 
  460 
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Table 1: Characteristics of the analysis cohort of 156,947 women commencing IVF 461 
treatment for infertility in the UK in 2003-2010 (with outcomes assessed up to June 462 
2012).  463 
Characteristic For all cycles combineda For first cycleb 
 
Number of women 
 
 
156,947
  
156,947 
 
Total number of cycles 
    1 
    2 
    3 
    More than 3 
 
93,494 
39,707 
15,507 
8,239
 
(59.6%) 
(25.3%) 
(9.9%) 
(5.2%) 
  
 
Number of cycles 
 
 
257,398
  
156,947 
 
Live- births (% per cycle) 70,093 (27.2%) 46,333 (29.5%) 
Woman’s age (years) 
    Median (1st quartile, 3rd quartile) 
 
35
 
(32, 38) 
 
35 
 
(32, 38) 
Duration of infertility (years) 
    Median (1st quartile, 3rd quartile) 
    Missing  
 
4 
11,165
 
(2, 6) 
(4.3%) 
 
3 
6,586 
 
(2, 5) 
(4.0%) 
Causes of infertility (non-exclusive) 
    Tubal 
    Ovulatory 
    Endometriosis 
    Male cause  
 
46,535 
34,473 
15,889 
105,014
 
(18.1%) 
(13.4%) 
(6.2%) 
(40.8%) 
 
28,181 
21,582 
9,654 
63,023 
 
(18.0%) 
(13.8%) 
(6.1%) 
(40.2%) 
Treated with ICSI 123,009 (47.8%) 68,608 (43.7%) 
Treated with sperm donation 8,067 (3.1%) 4,781 (3.05%) 
Treated with oocyte donation 7,223 (2.8%) 3,587 (2.3%) 
Oocytes retrieved (own) 
    Median (1st quartile, 3rd quartile) 
9 (5, 13) 9 (5, 13) 
Embryo transfer events per cycle 
    No embryos transferred 
    Fresh embryo transfer only 
    Fresh and frozen embryo transfer 
 
31,738 
199,713 
25,947
 
(12.3%) 
(77.6%) 
(10.1%) 
 
20,794 
119,462 
16,691 
 
(13.3%) 
(76.1%) 
(10.6%) 
 
Number of embryo transfer events 
 
 
257,581
  
157,043 
 
Number of embryos transferred per 
embryo transfer eventc  
    1 
    2 
    3-4 
 
 
44,330 
201,888 
11,363
 
 
(17.2%) 
(78.4%) 
(4.4%) 
 
 
29,942 
122,483 
4,618 
 
 
(19.1%) 
(78.0%) 
(3.0%) 
a The unit of analysis here is cycle (with results the average across all cycles per woman)  464 
b As this is just one cycle the unit of analysis is the women at their first treatment cycle 465 
c As there are a variable number of transfer events per treatment cycle (which includes all 466 
subsequent fresh and frozen transfer events) the % is per the number of transfer events (not 467 
per cycle)  468 
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Table 2: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 156,947 women undergoing 469 
257,398 cycles of IVF 470 
 471 
Cycle 
number 
N Cycles N live-
births 
Live-birth rate 
within each cycle 
% (95%CI) 
Cumulative live-birth across all cycles using different estimates % (95%CI) 
Optimal estimate Conservative 
estimate 
Age adjusted 
estimate 
Prognostic 
adjusted estimatea 
1st 156,947 46,333 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 
2nd 63,453 15,825 24.9 (24.6, 25.3) 47.1 (46.8, 47.4) 40.5 (40.3, 40.8) 46.7 (46.4, 47.0) 45.1 (44.9, 45.4) 
3rd 23,746 5,358 22.6 (22.0, 23.1) 59.0 (58.7, 59.4) 44.6 (44.4, 44.9) 58.3   (57.9, 58.6) 54.3 (54.0, 54.6)
4th 8,239 1,690 20.5 (19.6, 21.4) 67.4 (67.0, 67.9) 46.1 (45.8, 46.3) 66.4 (66.0, 66.9) 59.8 (59.4, 60.1) 
5th 3,012 553 18.4 (17.0, 19.7) 73.4 (72.8, 74.0) 46.6 (46.3, 46.8) 72.2 (71.6, 72.7) 63.1 (62.6, 63.5) 
6th 1,162 202 17.4 (15.2, 19.6) 78.0 (77.3, 78.8) 46.8 (46.5, 47.0) 76.7 (76.0, 77.5) 65.3 (64.8, 65.8) 
7th 458 79 17.2 (13.8, 20.7) 81.8 (80.8, 82.8) 46.9 (46.7, 47.2) 80.5 (79.5, 81.5) 66.8 (66.2, 67.4) 
8th 199 37 18.6 (13.2, 24.0) 85.2 (83.9, 86.5) 46.9 (46.7, 47.2) 83.7 (82.4, 85.0) 68.0 (67.3, 68.7) 
9th 83 13 15.7 (7.8, 23.5) 87.5 (85.9, 89.1) 46.9 (46.7, 47.2) 86.3 (84.7, 87.9) 68.7 (68.0, 69.5) 
 472 
a In these estimates we assumed that 30% of women who were lost to follow-up did so because of poor prognosis; 30% is conservative since the 473 
proportions suggested by the results from age- adjusted results (shown in column 7) is approximate 3%. 474 
Note it is not possible to calculate an oocyte-adjusted estimate for the whole cohort due to the presence of women using donor oocytes. 475 
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Table 3: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 133,379 women, undergoing 476 
217,113 cycles of IVF, who were younger than 40 years at their first treatment cycle and using their own oocytes. 477 
 478 
Cycle 
number 
N Cycles N live-
births 
Live-birth rate 
within each cycle 
% (95%CI) 
Cumulative live-birth across all cycles using different estimates % (95%CI) 
Optimal estimate Conservative 
estimate 
Previous oocyte 
yield-adjusted 
estimate 
Prognostic 
adjusted estimatea 
1st 133,379 43,019 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 
2nd 53,568 14,532 27.1 (26.8, 27.5) 50.6 (50.3, 50.9) 44.3 (44.0, 44.5) 50.7 (50.4, 51.1) 48.7 (48.4, 49.0) 
3rd 19,719 4,793 24.3 (23.7, 24.9) 62.6 (62.3, 63.0) 48.6 (48.4, 48.9) 62.7 (62.3, 63.1) 58.0 (57.7, 58.4) 
4th 6,641 1,419 21.4 (20.4, 22.4) 70.6 (70.1, 71.1) 50.1 (49.8, 50.3) 70.5 (70.1, 71.0) 63.3 (62.9, 63.7) 
5th 2,357 449 19.0 (17.5, 20.6) 76.2 (75.6, 76.8) 50.6 (50.3, 50.8) 76.0 (75.4, 76.6) 66.4 (66.0, 66.9) 
6th 882 150 17.0 (14.5, 19.5) 80.3 (79.5, 81.0) 50.7 (50.5, 51.0) 80.1 (79.3, 80.8) 68.4 (67.8, 68.9) 
7th 335 58 17.3 (13.3, 21.4) 83.7 (82.7, 84.7) 50.8 (50.5, 51.1) 83.4 (82.4, 84.4) 69.8 (69.1, 70.4) 
8th 131 25 19.1 (12.4, 25.8) 86.8 (85.4, 88.2) 50.9 (50.6, 51.1) 86.5 (85.1, 87.9) 70.9 (70.1, 71.6) 
9th 51 10 19.6 (8.7, 30.5) 89.4 (87.6, 91.2) 50.9 (50.6, 51.2) 88.8 (87.2, 90.3) 71.6 (70.8, 72.5) 
 479 
a In these estimates we assumed that 30% of women who were lost to follow-up did so because of poor prognosis; 30% is conservative since the 480 
proportions suggested by the results from previous oocyte yield-adjusted results (shown in column 7) is approximate 3%. 481 
Note it is not possible to calculate an age-adjusted estimate in this group because it is already age stratified and there is too little age variation 482 
within this group to adjust for it. 483 
 484 
All UK assisted reproductive therapy
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